Link to this page
National Cancer Institute Thesaurus
| Preferred Name | Teniposide | |
| Synonyms |
[5R-[5Alpha,5a beta,8a alpha, 9beta(R*)]]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[[4,6-O-(2-thienylmethylene)-beta-D-glucopyranosyl]oxy]furo[3',4':6,7]-naphtho[2,3-d]-1,3-dioxol-6(5aH)-one 4'-Demethylepipodophyllotoxin 9-(4,6-O-2-Thenylidene-beta-D-glucopyranoside) Thenylidene Lignan 4'-Demethylepipodophyllotoxin-beta-D-thenylidine Glucoside EPT PTG TENIPOSIDE Teniposide VM 26 VM-26 Vehem Vumon teniposide |
|
| Definitions |
A semisynthetic derivative of podophyllotoxin with antineoplastic activity. Teniposide forms a ternary complex with the enzyme topoisomerase II and DNA, resulting in dose-dependent single- and double-stranded breaks in DNA, DNA: protein cross-links, inhibition of DNA strand religation, and cytotoxicity. This agent acts in the late S or early G phase of the cell cycle. (NCI04) |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C857 |
|
| ALT_DEFINITION |
An anticancer drug that is a podophyllotoxin derivative and belongs to the family of drugs called mitotic inhibitors.
|
|
| CAS_Registry |
29767-20-2
|
|
| Chemical_Formula |
C32H32O13S
|
|
| code |
C857
|
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC HemOnc
|
|
| DEFINITION |
A semisynthetic derivative of podophyllotoxin with antineoplastic activity. Teniposide forms a ternary complex with the enzyme topoisomerase II and DNA, resulting in dose-dependent single- and double-stranded breaks in DNA, DNA: protein cross-links, inhibition of DNA strand religation, and cytotoxicity. This agent acts in the late S or early G phase of the cell cycle. (NCI04)
|
|
| Display_Name |
Teniposide
|
|
| FDA_UNII_Code |
957E6438QA
|
|
| FULL_SYN |
[5R-[5Alpha,5a beta,8a alpha, 9beta(R*)]]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[[4,6-O-(2-thienylmethylene)-beta-D-glucopyranosyl]oxy]furo[3',4':6,7]-naphtho[2,3-d]-1,3-dioxol-6(5aH)-one 4'-Demethylepipodophyllotoxin 9-(4,6-O-2-Thenylidene-beta-D-glucopyranoside) Thenylidene Lignan 4'-Demethylepipodophyllotoxin-beta-D-thenylidine Glucoside EPT PTG TENIPOSIDE Teniposide VM 26 VM-26 Vehem Vumon teniposide
|
|
| Has_Target | ||
| Is_Value_For_GDC_Property | ||
| label |
Teniposide
|
|
| Legacy Concept Name |
Teniposide
|
|
| Maps_To |
Teniposide
|
|
| NCI_Drug_Dictionary_ID |
43671
|
|
| NSC Number |
122819
|
|
| PDQ_Closed_Trial_Search_ID |
43671
|
|
| PDQ_Open_Trial_Search_ID |
43671
|
|
| Preferred_Name |
Teniposide
|
|
| prefixIRI |
Thesaurus:C857
|
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance
|
|
| UMLS_CUI |
C0039512
|
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |